
    
      During the course of the study, the use of optical coherence tomography (OCT)-guided therapy
      became a standard of care accepted by health authorities and the ophthalmology community in
      the treatment of neovascular (wet) age-related macular degeneration (nAMD), Novartis decided
      on 08-Oct-2014 the early termination of the study. Therefore the 12-month cutoff date was not
      reached and the related analyses were not performed.
    
  